Angiotensin II Antagonism of TGF-Beta 1

Completed · Not applicable

Conditions studied: Diabetic Nephropathy, Hypertension

In brief

Diabetic nephropathy is a frequent microvascular complication that occurs in approximately 40% of patients with either type 1 or type 2 diabetes. The most common cause of end-stage renal disease (ESRD) in the United States and in the developed world is diabetic nephropathy. Currently, more than half the United States ESRD population has diabetes. More effective therapies to prevent and treat diabetic nephropathy are urgently needed. One way to increase therapeutic effectiveness is to refine treatment targets based on improved understanding of how treatments modulate disease processes. The purpose of this study is to determine whether a treatment for diabetic nephropathy, the angiotensin receptor blocker candesartan, modifies mediators of kidney injury independent of blood pressure and the relationships to drug dose.

Key facts

Study ID

NCT00320970

Run by

Providence Health & Services

People needed

36

Starts

2002-08-01

Expected to finish

2004-09-01

Last updated by the study team

2007-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Type 2 diabetes
• Nephropathy (proteinuria >500 mg/day)
• Chronic Hypertension (as determined by current antihypertensive therapy and/or an average of diastolic blood pressure greater than 90 mmHg or greater or systolic blood pressure of 140 mmHg confirmed on at least two subsequent visits over one week or more).

You may not qualify if…

• Conditions associated with elevated TGF-Beta (e.g. rheumatoid arthritis, cancer, etc.).
• Conditions associated with alterations in serum levels of PIP and/or CITP (liver cirrhosis, osteoporosis, hyperthyroidism, multiple myeloma, osteolytic metastases, and systemic glucocorticoid treatment
• History of Stage III hypertension (diastolic BP > 110 mmHg or systolic BP > 180 mmHg) or a history of hypertensive urgency or emergency.
• NYHA Class III or IV heart failure
• Calculated creatinine clearance of less than 30 ml/min or serum creatinine > 3 mg/dL
• HbA1c > 10%
• Patients unable to be withdrawn for 2 weeks from AT-II antagonist or ACE- inhibitor therapy
• Blood Pressure <140/90 is unachievable in the absence of an AT-II antagonist or ACE-inhibitor

Where it is running

• Providence Medical Research Center — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.